GSK wins $235 million from Teva in Coreg patent trial

(Reuters) - A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Coreg | Health | Legislation